Comprehensive biopharmaceutical characterization has long outpaced what any single analytical technique can deliver. Waters Corporation has released version 3.10.1 of its Empower Chromatography Data System (CDS), extending its orthogonal analytical toolkit with advanced SEC-MALS capabilities, in-line LC-MS deconvolution, and enhanced capillary electrophoresis workflows within a single compliant-ready software environment for regulated biopharma laboratories.
Why Does Biopharmaceutical Characterization Require Multiple Orthogonal Techniques?
Modern biotherapeutics resist full characterization by any single measurement. Each modality, from monoclonal antibodies and antibody-drug conjugates to oligonucleotides, vaccines, and gene therapy products, carries distinct critical quality attributes that require separate physical measurement principles to resolve. The FDA's ICH Q2(R2) Validation of Analytical Procedures guidance, finalized in March 2024, formalizes this expectation, requiring that complementary measurements across size, mass, and charge support any claim of product identity, purity, and structural integrity.
Running SEC-MALS, LC-MS, and capillary electrophoresis across separate software environments has carried real operational costs for QC laboratories. Fragmented platforms mean separate validation timelines, split audit trails, and reliance on specialist expertise for tools sitting outside the primary CDS. These constraints grow harder to absorb as biopharma pipelines widen to include more structurally diverse modalities.
Working in analytical science?
Register for a FREE Separation Science account to subscribe to the Separation Science Newsletter.
Empower CDS 3.10.1 consolidates three orthogonal technique categories within one compliant, traceable platform for biopharmaceutical characterization. Key capabilities in this release include:
- Advanced SEC-MALS: Six new fitting algorithms for larger and more complex biomolecules, streamlined analysis for conjugated therapeutics, uncertainty analysis for reported results, and improved baseline handling for low-level aggregate and impurity detection
- In-line LC-MS deconvolution: Empower CDS now converts mass spectra from Waters SQD2 and ACQUITY QDa II detectors into molecular mass information directly, removing the need for standalone deconvolution software
- Enhanced capillary electrophoresis: Unlimited isoelectric point (pI) markers for cIEF analysis and deposition time and velocity-corrected area support for CGE size variant workflows
- Data security and integrity: Expanded technical controls reduce the potential for human error and bias, with updated Chinese Pharmacopoeia compliance calculations
Size exclusion chromatography plays a broader role across the biopharma development lifecycle than any single workflow suggests, spanning aggregate quantification, viral vector analysis, and lipid nanoparticle characterization, all areas where the SEC-MALS enhancements in this release are directly applicable.
Empower CDS 3.10.1 Extends Orthogonal Coverage Across The Full Biotherapeutic Portfolio
SEC-MALS biopharmaceutical characterization gains the most breadth in this release. Six new fitting algorithms widen the range of biomolecules that Empower can reliably analyze, uncertainty analysis adds a statistical confidence layer to reported results, and improved baseline handling sharpens detection of low-level aggregates. ADCs and PEGylated proteins gain dedicated workflows built for conjugated formats.
Integrating spectral deconvolution for SQD2 and QDa II detectors directly into Empower CDS removes a friction point that has long sat outside regulated LC-MS workflows. Laboratories can now generate molecular mass confirmation data in a validated, auditable environment without transferring spectra to a separate tool or requiring an MS specialist for routine identity checks. For QC settings, keeping deconvolution inside the CDS also keeps it inside the audit trail.
Capillary electrophoresis workflows gain targeted improvements at both the cIEF and CGE levels. Unlimited pI markers extend the range of isoelectric focusing characterization, while velocity-corrected area reporting in CGE improves quantitative accuracy for size variant data. Both updates run within the same compliant Empower environment as the SEC-MALS and LC-MS workflows.
| Technique | New Capability In 3.10.1 | Analytical Benefit |
|---|---|---|
| SEC-MALS | Six new fitting algorithms; uncertainty analysis | Reliable characterization of larger, more structurally complex biomolecules |
| SEC-MALS | Conjugated therapeutic workflows | ADC and PEGylated protein analysis within a compliant environment |
| SEC-MALS | Enhanced baseline handling | Better detection of low-level aggregates and impurities |
| LC-MS | In-line deconvolution for SQD2 and QDa II | Molecular mass confirmation without separate deconvolution software |
| CE (cIEF) | Unlimited pI markers | Extended charge variant resolution and isoelectric point monitoring |
| CE (CGE) | Velocity-corrected area support | Improved quantitative accuracy for size variant analysis |
| Data integrity | Expanded technical controls | Reduced potential for human error in compliance-critical workflows |
| Regulatory | Chinese Pharmacopoeia calculations | Alignment with current NMPA submission requirements |
Waters reports that Empower Software supports regulatory submissions for more than 80% of novel drugs globally. Native mass analysis, aggregate characterization, and charge variant workflows represent the core of what these laboratories rely on Empower to manage, and all three gain capability in this release. Empower CDS 3.10.1 is available now through Waters' software upgrade program.
A Compliant Platform For The Full Analytical Picture
Empower CDS 3.10.1 gives biopharma QC and method development laboratories a single validated environment for SEC-MALS, LC-MS deconvolution, and capillary electrophoresis data. Consolidating these workflows under one audit trail reduces the validation overhead that has made multi-technique characterization operationally intensive. For laboratories managing increasingly complex therapeutic portfolios, that consolidation has practical value beyond the individual technique upgrades.
This article is based on a press release issued by Waters Corporation and was produced under Separation Science's AI Editorial Guidelines.
